Newsfeeds Archive - Page 42 of 56

3 minute read

Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS’ Published Results

November 18, 2:28 PM

(Part two of a four-part series) See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes

CMPS

2 minute read

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial

By Lara Goldstein

November 17, 3:48 PM

Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science Corp.

KONEF

2 minute read

Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes

By Lara Goldstein

November 16, 8:57 PM

(Part one of a four-part series)

CMPS

2 minute read

Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon

By Lara Goldstein

November 16, 1:47 PM

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.

AGNPF

2 minute read

Biomind Labs: Q3 Financials & FDA Approval For New Chemical Entity Targeting Treatment-Resistant Depression

By Lara Goldstein

November 15, 4:36 PM

Next-gen psychedelics developer Biomind Labs Inc.

BMNDF

1 minute read

This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split

By Lara Goldstein

November 15, 4:22 PM

Psychedelics biotech firm Clearmind Medicine Inc.

CMND

2 minute read

Cybin Shares Q2 Financial & Business Results, Focus On Licensing Deals For Preclinical Assets

By Lara Goldstein

November 15, 4:13 PM

Cybin Inc. (NYSE: CYBN) reported its unaudited financial results for its second quarter ended September 30, 2022, and provided business highlights for the period.

CYBN

2 minute read

Mydecine’s Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months

By Lara Goldstein

November 15, 1:25 PM

Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business highlights for the three and nine months ended September 30, 2022.

MYCOF

4 minute read

Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup

By Lara Goldstein

November 15, 12:46 PM

Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics

ATAI

3 minute read

Reunion Neuroscience Presents Q2 2023 Financial Results & Pipeline Update

By Lara Goldstein

November 14, 3:58 PM

Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022.

REUN